NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Cover of Accelerating the Development of New Drugs and Diagnostics

Accelerating the Development of New Drugs and Diagnostics

Maximizing the Impact of the Cures Acceleration Network

Workshop Summary

.

Washington (DC): National Academies Press (US); .
ISBN-13: 978-0-309-26116-6ISBN-10: 0-309-26116-3

Excerpt

This public workshop considered options and opportunities to maximize the usefulness and impact of the Cures Acceleration Network (CAN) program in order to advance translational sciences. The workshop objectives were to:

  • Identify and catalog potential tools, methods, and approaches that hold promise for accelerating translational science.

    Consideration of such promising approaches will draw from the experiences of existing activities at other federal agencies related to the goals of CAN—for example, FDA, the U.S. Centers for Disease Control and Prevention (CDC), and the Agency for Healthcare Research and Quality (AHRQ).

  • Discuss the authorities conferred to CAN and identify strategies for effectively using those authorities.

    Consideration of the CAN authorities will specifically explore the flexible research, or “other transaction,” authority and will reference existing efforts in which such authority is currently applied across other federal agencies—for example, DARPA, the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).

  • Explore promising models for public–private collaborations that could be strengthened or facilitated by activities under CAN.

    Discuss barriers to such collaborations and identify opportunities and potential solutions for moving past the identified barriers.

    Discuss the respective roles of multiple sectors, including, for example, the pharmaceutical and biotechnology industries, venture capital and private equity, and patient advocacy groups.

  • Identify barriers and potential solutions to facilitate coordination of activities under CAN with the FDA regulatory review process and timelines.

Contents

Rapporteurs: Steve Olson, Anne B. Claiborne

This study was supported by contracts between the National Academy of Sciences and Department of Health and Human Services (Contract Nos. N01-OD-4-2139 and HHSF223001003T), Abbott Pharmaceuticals, American Diabetes Association, American Society for Microbiology, Amgen Inc., Association of American Medical Colleges, Bristol-Myers Squibb, Burroughs Wellcome Fund, Celtic Therapeutics, LLLP, Critical Path Institute, Doris Duke Charitable Foundation, Eli Lilly & Co., FasterCures, Foundation for the NIH, Friends of Cancer Research, GlaxoSmithKline, Janssen Research & Development, LLC, March of Dimes Foundation, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, and Pfizer Inc.

Suggested citation:

IOM (Institute of Medicine). 2012. Accelerating the Development of New Drugs and Diagnostics: Maximizing the Impact of the Cures Acceleration Network: Workshop Summary. Washington, DC: The National Academies Press.

The views presented in this publication do not necessarily reflect the views of the organizations or agencies that provided support for the project.

NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.

Copyright © 2012, National Academy of Sciences.
Bookshelf ID: NBK100139PMID: 23230580
PubReader format: click here to try

Views

Related information

Related citations in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...